Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | KEYNOTE-412: pembrolizumab with CRT vs placebo plus CRT for locally advanced HNSCC

Jean-Pascal Machiels, MD, PhD, Cliniques Universitaires Saint-Luc, Brussels, Belgium, presents results from the KEYNOTE-412 study (NCT03040999), a Phase III trial evaluating pembrolizumab with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma (HNSCC). Pembrolizumab + CRT was associated with a favorable trend toward improved event-free survival vs placebo + CRT in patients with locally advanced HNSCC, but the difference did not reach statistical significance. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.